On October 11, 2022 Orthofix and SeaSpine announced an agreement to merge that is expected to close in the first quarter of 2023. Please also view the presentation and press release describing the merger, which are both posted on our website. 1 ORTHOFIX Improving patient mobility through innovation Forward-Looking Statements and Non-GAAP Financial Measures 2 2 Except for historical information contained herein, the statements made in this presentation constitute forward-looking statements that involve certa ...

Financial Data and Key Metrics Changes - Total revenue for Q3 2022 was $114 million, increasing 1% over 2021 on a reported basis and 5% on a constant currency basis [5][14] - GAAP gross margin in Q3 2022 was 73%, down from 75% in the prior year period [14] - GAAP loss per share was $0.53 compared to a loss of $0.11 in Q3 2021, while adjusted EPS was $0.13 compared to $0.10 in the prior year [16][14] - Adjusted EBITDA margin increased to 13% of net sales compared to 11% in Q3 2021 [15] Business Line Data and Key Metrics Changes - Bone Growth Therapies (BGT) sales were $46.5 million, up 3% on both a reported and constant currency basis [6] - Spinal Implants revenue was down approximately 8% on a reported basis and 7% on a constant currency basis [6] - Biologics revenue was up 8% on a reported and constant currency basis [7] - Global Orthopaedics revenue was up 6% on a reported basis and 19% on a constant currency basis [7] Market Data and Key Metrics Changes - U.S. total net sales were $88 million, or 77% of total net revenue, up approximately 2% versus the prior year [14] - International total net sales were $26 million, or 23% of total revenue, up 13% in constant currency over Q3 2021 [14] Company Strategy and Development Direction - The company is focused on solidifying its position in regenerative healing technologies and driving sustainable profitable growth through innovation and differentiation [18] - The planned merger with SeaSpine aims to create a leading global Spine and Orthopedics company with a combined revenue of nearly $700 million [12][13] - The company is investing in expanding its commercial channels and optimizing its product offerings to enhance market access [11] Management's Comments on Operating Environment and Future Outlook - Management noted ongoing macro headwinds, including hospital staffing issues and inflation sensitivity affecting patient behavior [17] - Key products like AccelStim and Virtuos are gaining initial momentum, but significant revenue contributions are not expected until 2023 [17] - The company remains optimistic about future growth driven by new product innovations and commercial channel initiatives [21] Other Important Information - The company received a 2022 Spine Technology Award for the Virtuos Lyograf, highlighting its innovative product offerings [10] - The merger with SeaSpine is expected to enhance the combined company's competitive position and expand its product portfolio [13][46] Q&A Session Summary Question: Can you quantify the commercial channel initiatives and investments? - Management discussed investments in building the fracture channel and noted that results are being seen in the Orthopedics business with 19% growth [25][26] Question: What are the dynamics regarding procedure complexity post-COVID? - Management observed an increase in procedures but a decrease in levels per procedure, attributing this to various macroeconomic factors [28] Question: How should we think about the overall BGT portfolio growth profile with AccelStim? - Management indicated that AccelStim has positively impacted the acute fracture channel and expects continued growth in the BGT area [31][32] Question: Any updates on the M6 two-level study? - Management confirmed ongoing patient enrollment and increased efforts to complete the study as quickly as possible [36][38] Question: What are the implications of the merger on distribution channels? - Management stated that separate channels for BGT and orthopedics will remain, but there are significant opportunities for leveraging combined distribution efforts [45][46]

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 10-Q (Mark one) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2022 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to . Commission File Number: 0-19961 ORTHOFIX MEDICAL INC. (Exact name of registrant as specified in its charter) Delaware 98-1340767 (State or other jurisd ...

ORTHOFIX® 1 Improving patient mobility through innovation Forward-Looking Statements and Non-GAAP Financial Measures 2 2 Except for historical information contained herein, the statements made in this presentation constitute forward-looking statements that involve certain risks and uncertainties. These forward-looking statements are based on our beliefs and expectations as of August 5, 2022, and we do not undertake any obligation to revise or update such forward looking statements, which speak only as of su ...

Orthofix Medical Inc. (NASDAQ:OFIX) Q2 2022 Earnings Conference Call August 5, 2022 8:30 AM ET Company Participants Alexa Huerta – Senior Director-Investor Relations Jon Serbousek – President and Chief Executive Officer Doug Rice – Chief Financial Officer Conference Call Participants Mathew Blackman – Stifel Jeffrey Cohen – Ladenburg Jim Sidoti – Sidoti and Company Operator Hello, and a warm welcome to Orthofix Medical’s Q2 2022 Earnings Call. My name is Melissa, and I’ll be your operator today. [Operator I ...

FORM 10-Q (Mark one) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2022 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to . Commission File Number: 0-19961 ORTHOFIX MEDICAL INC. (Exact name of registrant as specified in its charter) Delaware 98-1340767 (State or other jurisdictio ...

Orthofix Medical Inc. (NASDAQ:OFIX) Q1 2022 Earnings Conference Call May 6, 2022 8:30 AM ET Company Participants Jon Serbousek – Director, President and Chief Executive Officer Doug Rice – Chief Financial Officer Alexa Huerta – Senior Director of Investor Relations and Finance Conference Call Participants Mathew Blackman – Stifel Financial Corp. Jeffrey Cohen – Ladenburg Thalmann & Co. Inc. Jim Sidoti – Sidoti & Company, LLC Operator Good morning, everyone and welcome to today's Orthofix Medical First Quart ...

Financial Performance - Net sales for the three months ended March 31, 2022, were $106,418 thousand, a slight increase from $105,593 thousand in the same period of 2021, representing a growth of approximately 0.8%[16] - Gross profit for the same period was $78,100 thousand, down from $79,679 thousand in 2021, indicating a decrease of about 2%[16] - The operating loss for Q1 2022 was $3,078 thousand, compared to a loss of $2,916 thousand in Q1 2021, reflecting a deterioration of approximately 5.5%[16] - The net loss for the three months ended March 31, 2022, was $4,460 thousand, an improvement from a net loss of $5,816 thousand in the prior year, showing a reduction of about 23.3%[16] - The Company reported a comprehensive loss of $5,622 thousand for Q1 2022, compared to a comprehensive loss of $7,389 thousand in the same period of 2021, indicating an improvement of approximately 23.9%[16] - Total EBITDA for the three months ended March 31, 2022, was $3,502,000, compared to $1,837,000 in 2021[47] - The Company reported a loss before income taxes of $4,389,000 for the three months ended March 31, 2022, compared to a loss of $6,023,000 in 2021[47] Cash and Liquidity - Cash, cash equivalents, and restricted cash at the end of the period were $71,917 thousand, down from $95,057 thousand at the end of Q1 2021, representing a decrease of approximately 24.4%[18] - The company anticipates that its cash and cash equivalents, investments, and access to revolving credit will be sufficient to meet its anticipated cash requirements[14] - The Company had no borrowings outstanding under the secured revolving credit facility as of March 31, 2022, and was in compliance with all required financial covenants[25] Inventory and Assets - Total inventories as of March 31, 2022, were $88,832 thousand, an increase from $82,974 thousand at the end of 2021, indicating a rise of about 7%[23] - As of March 31, 2022, the total Right-of-Use (ROU) assets increased to $25,213,000 from $21,755,000 as of December 31, 2021, representing a growth of approximately 15.5%[24] - The total lease liabilities rose to $27,543,000 as of March 31, 2022, compared to $25,757,000 at the end of 2021, indicating an increase of about 6.9%[24] Research and Development - Research and development expenses for Q1 2022 were $11,212 thousand, compared to $10,897 thousand in Q1 2021, reflecting an increase of approximately 2.9%[16] Shareholder Information - The weighted average number of common shares outstanding increased to 19,841,822 in Q1 2022 from 19,474,384 in Q1 2021, representing an increase of about 1.9%[17] - Weighted average common shares for diluted EPS calculations were 19,897,695 for the three months ended March 31, 2022, compared to 19,526,872 in 2021[54] - Share-based compensation expense totaled $4,332,000 for the three months ended March 31, 2022, compared to $3,721,000 in 2021[50] Segment Performance - Global Spine segment net sales were $82,655,000, with Bone Growth Therapies decreasing by 2.3% to $41,948,000, while Spinal Implants increased by 3.6% to $26,615,000[41] - Global Orthopedics segment net sales were $23,763,000, reflecting a 2.2% increase from $23,253,000 in 2021[41] Other Financial Metrics - The allowance for expected credit losses increased to $5,389,000 as of March 31, 2022, from $4,506,000 in 2021[43] - The effective tax rate for the three months ended March 31, 2022, was (1.6%), down from 3.4% in 2021, primarily due to certain losses not benefitted[52] - The Company recognized a contract liability ending balance of $1,396,000 for the Accelerated and Advanced Payment Program, down from $13,851,000 in 2021[44] - The Company accrued $5,400,000 related to the Italian Medical Device Payback (IMDP) as of March 31, 2022, which is classified within other long-term liabilities[39] - The Company recorded cash paid for operating leases of $1,068,000 for the three months ended March 31, 2022, compared to $1,147,000 for the same period in 2021[24] - The Company recorded an expense of $300,000 and $400,000 for the IMDP for the three months ended March 31, 2022, and 2021, respectively[39] Fair Value Measurements - The fair value of Neo Medical preferred equity securities increased to $6,084,000 as of March 31, 2022, up from $5,413,000 at the end of 2021, reflecting a growth of approximately 12.3%[26] - The fair value of Neo Medical Convertible Loans decreased to $5,780,000 as of March 31, 2022, down from $7,148,000 at the beginning of the year, a decline of about 19.2%[31] - The estimated fair value of the Spinal Kinetics contingent consideration was $11,700,000 as of March 31, 2022, down from $17,200,000 at the start of the year, a decrease of approximately 32.5%[36] - The Company recognized a cumulative unrealized gain of $413,000 on Neo Medical preferred equity securities as of March 31, 2022[29]

©2022 SeaSpine Orthopedics Corporation. All rights reserved | 1 Operate in the Now Keith C. Valentine President & Chief Executive Officer March 11, 2022  SeaSpine. Forward-looking Statements & Disclaimer This presentation is for informational purposes only and is not an offer to sell or a solicitation of an offer to buy any securities of SeaSpine Holdings Corp. ("SeaSpine" or the "Company"). This presentation includes certain information obtained from trade and statistical services, third-party publication ...

Orthofix Medical Inc. (NASDAQ:OFIX) Q4 2021 Results Conference Call February 25, 2022 8:30 AM ET Company Participants Alexa Huerta - Senior Director of Investor Relations Jon Serbousek - President & Chief Executive Officer Doug Rice - Chief Financial Officer Conference Call Participants Mathew Blackman - Stifel Jeffrey Cohen - Ladenburg Jim Sidoti - Sidoti & Company Operator Good morning and welcome to today's Orthofix Medical Inc. Fourth Quarter 2021 Earnings Conference Call. My name is Candy and I will be ...